Sana Biotechnology
Clinical trials sponsored by Sana Biotechnology, explained in plain language.
-
Experimental donor immune cells target Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial tests SC262, a therapy made from donor immune cells (CAR T cells) designed to attack a protein called CD22 on lymphoma cells. It is for people with non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The main goal is to check …
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental Donor-Cell therapy takes aim at tough autoimmune diseases
Disease control OngoingThis early-stage study tests a therapy called SC291, made from donor immune cells, in 7 people with severe lupus or vasculitis that hasn't improved with standard treatments. The goal is to see if it is safe and tolerable, and to get a first look at whether it can control the dise…
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Engineered donor cells take on tough lymphomas and leukemias
Disease control OngoingThis early-phase study tests SC291, a CAR T-cell therapy made from donor cells, in 16 adults with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal is to check safety and see if the treatment can shrink tumors. Because it uses donor cell…
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC